Klivira
Request demo

Optimizing Trelegy Prior Authorization for Gastroenterology Workflows

Navigating Trelegy prior authorization for gastroenterology practices requires a robust system to manage diverse drug portfolios and complex payer requirements efficiently.

Gastroenterology departments face significant prior authorization burdens across biologics, procedures, and advanced imaging. While Trelegy is not a primary GI therapeutic, its status as a high-volume PA drug highlights the broader challenges of managing complex prior authorization workflows within any specialty. Klivira provides comprehensive automation to streamline these processes, ensuring efficient handling of all drug and procedure PAs.

The Prior Authorization Landscape in Gastroenterology

Gastroenterology practices manage a substantial volume of prior authorization requests, driven by the chronic nature of many GI conditions and the complexity of treatments. Key categories include biologics for inflammatory bowel disease (IBD), advanced diagnostic imaging, and specialized endoscopic procedures. This creates a continuous administrative burden for revenue cycle and prior authorization teams.

High-Volume Prior Authorization Categories in Gastroenterology

  • IBD biologics, including TNF inhibitors, integrin inhibitors, and IL-12/23 inhibitors
  • Hepatitis C direct-acting antivirals, with distinct pathways for treatment-naive vs. experienced patients
  • Advanced imaging such as MRCP, MR enterography, and CT enterography for IBD assessment
  • Specific endoscopic procedures like capsule endoscopy (CPT 91110) and ERCP for defined indications
  • Specialty drugs for functional GI disorders, including agents for IBS-D, chronic constipation, and IBS-C
  • Non-routine colonoscopy surveillance requiring specific plan authorization

Trelegy: A High-Volume Prior Authorization Drug

Trelegy, a widely prescribed medication, is consistently flagged as a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. Its frequent PA requirement underscores the need for streamlined processes to avoid delays in patient care and revenue cycle disruption, regardless of the prescribing specialty.

Navigating Diverse Drug PAs within Gastroenterology Workflows

While Trelegy's primary indications are outside traditional gastroenterology, GI practices, particularly within multi-specialty health systems, frequently encounter a broad spectrum of prior authorization requests. The operational challenges of securing approval for high-volume PA drugs, whether for GI-specific biologics or other medications, share commonalities in documentation, payer portal navigation, and step therapy adherence. Efficient platforms must accommodate this diverse demand.

Klivira's Comprehensive PA Automation for Complex Specialties

Klivira’s platform is engineered to manage the intricate prior authorization demands of high-volume specialties like gastroenterology. By integrating with EMRs and payer portals, we automate the submission and tracking of diverse PA requests, from IBD biologics to other frequently authorized medications like Trelegy, ensuring consistency and compliance across the organization.

Streamlining Documentation and Mitigating Denial Risks

Common denial reasons in GI, such as insufficient disease severity documentation or step therapy non-compliance for IBD biologics, mirror challenges seen with other complex drug PAs. Klivira leverages payer-specific policy libraries and EMR data to proactively identify and fulfill documentation requirements, reducing denials for all high-volume prior authorizations, including those for Trelegy.

Frequently asked questions

How does Klivira handle the varied prior authorization requirements for drugs like Trelegy and GI biologics?

Klivira's platform uses a comprehensive payer-policy library and integrates with EMRs to extract relevant patient data. This enables the system to intelligently adapt to the specific documentation and step therapy requirements for a wide range of medications, from IBD biologics to high-volume drugs like Trelegy, ensuring accurate and compliant submissions.

What specific GI prior authorization challenges does Klivira address?

For gastroenterology, Klivira automates workflows for IBD biologics, Hep C DAAs, advanced imaging, and specific endoscopic procedures. This includes managing periodic re-authorizations for chronic treatments, distinguishing between treatment-naive vs. experienced pathways, and routing for medical-vs-pharmacy benefit splits.

Can Klivira integrate with our EMR to pull documentation for Trelegy prior authorizations and other drug PAs?

Yes, Klivira offers robust EMR integration, including SMART on FHIR capabilities, to automatically pull necessary clinical documentation. This streamlines the assembly of prior authorization requests for any medication, including Trelegy, by leveraging existing patient records and reducing manual data entry.

How does Klivira help avoid denials for high-volume drugs like Trelegy and other complex PAs?

Klivira mitigates denial risks by ensuring all required documentation is complete and accurate according to payer-specific policies. This includes validating disease severity, confirming step therapy compliance, and addressing common gaps like missing screening documentation, applicable to both GI-specific drugs and other high-volume PAs.

Does Klivira support both medical and pharmacy benefit prior authorizations for GI drugs?

Yes, Klivira's platform is designed to manage prior authorizations across both medical and pharmacy benefits. This is crucial for gastroenterology, where biologic agents for IBD may be administered via infusion (medical benefit) or self-injection (pharmacy benefit), ensuring seamless processing regardless of the benefit type.

Related coverage

Other trelegy prior authorization by payer

Other trelegy prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo